Uncover key drivers, emerging technologies, and competitive movements shaping the omics-based clinical trials market from 2025–2034 with trusted insights from The Business Research Company

What Is The Present And Forecasted Size Of The Omics-Based Clinical Trials Market?

The omics-based clinical trials market has shown robust expansion in recent years. Its valuation is anticipated to rise from $29.10 billion in 2024 to $31.71 billion in 2025, indicating a compound annual growth rate (CAGR) of 8.9%. The growth observed historically is attributable to an increasing volume of clinical trials incorporating omics technologies, a heightened emphasis on translational research, augmented governmental aid and financing, greater access to biobanks and biospecimens, and improved understanding of the advantages of precision therapies.

The omics-based clinical trials market is projected for significant expansion in the coming years. This market is anticipated to reach $44.08 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.6%. This projected growth is driven by several factors, including the increasing demand for personalized medicine, greater adoption of multi-omics approaches, the rising incidence of chronic and rare diseases, increased investment in genomic research and biotechnology, and an intensified focus on biomarker discovery. Key trends foreseen during this period involve enhancements in next-generation sequencing (NGS) technologies, the incorporation of artificial intelligence into omics platforms, technological progress in bioinformatics tools, innovations in proteomics and metabolomics platforms, and the comprehensive integration of multi-omics data.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27369&type=smp

What Underlying Factors Are Supporting The Omics-Based Clinical Trials Market Growth?

The omics-based clinical trials market is projected to expand due to the increasing demand for personalized medicine. Personalized medicine involves a medical strategy that customizes disease prevention, diagnosis, and treatment according to the unique characteristics of each patient. This demand is escalating, driven by advancements in genomic technologies that facilitate faster, more cost-effective analysis of individual genetic profiles to guide targeted treatments. Omics-based clinical trials bolster personalized medicine by enabling the identification of individual genetic, proteomic, and metabolic profiles, thereby allowing for more tailored and effective treatment strategies for each patient. For instance, in February 2023, the Personalized Medicine Coalition, a US-based professional membership organization, stated that in 2022, 12 new personalized medicines received approval, representing approximately 34% of all newly approved therapies, which signifies a substantial increase from prior years. This heightened demand for personalized medicine is thus a key driver for the growth of the omics-based clinical trials market.

How Does The Omics-Based Clinical Trials Market Differ By Segment?

The omics-based clinical trials market covered in this report is segmented

1) By Type: Genomics, Proteomics, Metabolomics, Transcriptomics

2) By Phase: Phase I, Phase II, Phase III, Phase IV

3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies

4) By Application: Oncology, Cardiovascular, Neurology, Infectious Diseases, Metabolic Disorders

5) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs), Hospitals And Diagnostic Laboratories

Subsegments:

1) By Genomics: Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing

2) By Proteomics: Protein Expression Profiling, Post-Translational Modifications Analysis, Protein-Protein Interaction Mapping

3) By Metabolomics: Targeted Metabolomics, Untargeted Metabolomics, Metabolic Flux Analysis

4) By Transcriptomics: Microarray Analysis, Single-Cell Transcriptomics, Gene Expression Profiling

What New Opportunities Are Emerging From Trends In The Omics-Based Clinical Trials Market?

Leading companies in the omics-based clinical trials market are increasingly adopting innovative solutions, such as HiFi sequencing technology, to enhance the accuracy, speed, and depth of multi-omics data analysis, which ultimately improves trial outcomes and personalized treatment strategies. HiFi sequencing is defined as a next-generation sequencing (NGS) technology that generates long, highly accurate reads through circular consensus sequencing (CCS), facilitating comprehensive and precise analysis of genomes, transcriptomes, and epigenomes. For instance, in October 2024, Pacific Biosciences of California Inc., a US-based biotechnology company, collaborated with the Agency for Science, Technology, and Research (A*STAR), a Singapore-based research and product development agency, and Macrogen Inc., a South Korea-based biotechnology company, to launch a cutting-edge laboratory. This facility was established in Singapore to accelerate genomics innovation utilizing advanced long-read sequencing technology. The lab empowers researchers to conduct sophisticated genomic studies with improved precision and speed, supporting a broad spectrum of applications, including whole genome sequencing, transcriptomics, epigenetics, and metagenomics. It also promotes collaboration among global scientists and local institutions, with the goal of accelerating discoveries in personalized medicine, rare disease diagnostics, and precision oncology. Additionally, the lab provides training programs and shared access to high-throughput sequencing infrastructure, fostering capacity-building and innovation throughout the Asia-Pacific region.

Who Are The Global Leaders Steering The Omics-Based Clinical Trials Market Forward?

Major companies operating in the omics-based clinical trials market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., GlaxoSmithKline Plc, Eli Lilly and Company, Novo Nordisk A/S, BioNTech SE, IQVIA Inc., Laboratory Corporation of America Holdings, ICON Public Limited Company, SGS Société Générale de Surveillance SA, Eurofins Scientific SE, Syneos Health Inc., Illumina Inc., Charles River Laboratories International Inc., Parexel International Corporation, Bruker Corporation, Fulgent Genetics Inc., Signios Biosciences, and BioAro Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/omics-based-clinical-trials-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Omics-Based Clinical Trials Market?

North America was the largest region in the omics-based clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omics-based clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27369&type=smp

Browse Through More Reports Similar to the Global Omics-Based Clinical Trials Market 2025, By The Business Research Company

Bitumen Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/bitumen-global-market-report

Asphalt Pavers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/asphalt-pavers-global-market-report

Polymer Coated Fabrics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/polymer-coated-fabrics-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model